Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Interest & Investment Income (2017 - 2025)

Historic Interest & Investment Income for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $7.0 million.

  • Protagonist Therapeutics' Interest & Investment Income fell 824.0% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.9 million, marking a year-over-year increase of 2184.02%. This contributed to the annual value of $26.3 million for FY2024, which is 7663.44% up from last year.
  • Latest data reveals that Protagonist Therapeutics reported Interest & Investment Income of $7.0 million as of Q3 2025, which was down 824.0% from $7.4 million recorded in Q2 2025.
  • Over the past 5 years, Protagonist Therapeutics' Interest & Investment Income peaked at $7.7 million during Q3 2024, and registered a low of $97000.0 during Q2 2021.
  • Over the past 5 years, Protagonist Therapeutics' median Interest & Investment Income value was $3.9 million (recorded in 2023), while the average stood at $3.6 million.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first tumbled by 8060.84% in 2021, then skyrocketed by 174508.2% in 2022.
  • Quarter analysis of 5 years shows Protagonist Therapeutics' Interest & Investment Income stood at $122000.0 in 2021, then soared by 1745.08% to $2.3 million in 2022, then skyrocketed by 88.45% to $4.2 million in 2023, then skyrocketed by 61.55% to $6.9 million in 2024, then increased by 2.86% to $7.0 million in 2025.
  • Its last three reported values are $7.0 million in Q3 2025, $7.4 million for Q2 2025, and $7.6 million during Q1 2025.